Samsung will debut at RSNA 2014 its RS80A ultrasound system, which is now available in the U.S.
Samsung will introduce at RSNA 2014 the RS80A ultrasound system, which is now available in the U.S.
The RS80A boasts sophisticated digital image processing and superb resolution to support accurate diagnosis, Samsung announced. It features an intuitive user interface and design developed to enhance workflows and support improved delivery, Samsung said.
The RS80A has applications for abdomen, vascular, cardiac, small organs, breast, urology, musculoskeletal, pediatric, fetal/obstetrics, and gynecology, Samsung said. The 23-inch HD LED display incorporates a 13.3-inch tilting tablet touch screen and a six-way motorized adjustable console.
The RS80A is made with S-Vision architecture, which is complemented by S-Vue transducer performance and ClearVision digital image processing, Samsung said. Its innovative enhancements include hybrid beam forming technology, Samsung said.
It performs through a comprehensive 3D technology suite that features Realistic Vue, which allows the user to select light source direction to display high-resolution 3D anatomy with exceptional detail and realistic depth perception, Samsung announced. The product also offers a selection of 2D, 3D, and 4D transducers.
[[{"type":"media","view_mode":"media_crop","fid":"29762","attributes":{"alt":"Samsung RS80A Ultrasound","class":"media-image media-image-right","id":"media_crop_9107388672509","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"3106","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"height: 440px; width: 440px; border-width: 0px; border-style: solid; margin: 1px; float: right;","title":"Samsung RS80A Ultrasound","typeof":"foaf:Image"}}]]
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
New Interventional Radiology Research Shows Merits of Genicular Artery Embolization for Knee OA
December 3rd 2024In a cohort of over 160 patients with knee osteoarthritis (OA), including grade 4 in nearly half of the cases, genicular artery embolization led to an 87 percent improvement in the quality of life index, according to research presented at the